MEG 21 with Supplamine Overview

  • Founded
  • 1997

Founded
  • Status
  • Private

  • Employees
  • 2

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $458K

  • Investors
  • 6

MEG 21 with Supplamine General Information

Description

Developer of a clinically proven anti-aging suite of products designed to treat aging skin. The company's products are made with proprietary small molecule drugs that inhibit a novel enzymatic pathway and causes the formation of reactive sugar, 3-deoxyglucosone which stimulates the production of Advanced Glycation End Products (AGEs), oxidative stress, and a cascade of inflammatory cytokines, enabling customers to use clinically validated and elegant cosmetic products that deliver long-lasting, measurable results.

Contact Information

Website
meg21.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Personal Products
Other Industries
Specialty Retail
Biotechnology
Other Pharmaceuticals and Biotechnology
Primary Office
  • 261 Old York Road
  • Suite 427
  • Jenkintown, PA 19046
  • United States
+1 (877) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MEG 21 with Supplamine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC 30-Aug-2018 $458K 000.00 Completed Generating Revenue
9. Later Stage VC 13-Jun-2018 00000 000.00 Completed Generating Revenue
8. Later Stage VC 00.00 000.00 Completed Generating Revenue
7. Seed Round 03-Feb-2016 00.00 Completed Generating Revenue
6. Grant 27-Jul-2010 00.00 Completed Generating Revenue
5. Angel (individual) 27-Jul-2010 00000 00.00 Completed Generating Revenue
4. Later Stage VC 19-Jun-2006 00.00 00.00 Completed Generating Revenue
3. Seed Round 12-Oct-1998 00000 00000 Completed Generating Revenue
2. Grant 01-Jan-1997 $100K Completed Startup
1. Joint Venture 01-Jan-1997 Completed Startup
To view MEG 21 with Supplamine’s complete valuation and funding history, request access »

MEG 21 with Supplamine Patents

MEG 21 with Supplamine Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160331798-A1 Natural product inhibitors of 3dg Inactive 30-May-2008 000000000
US-20130266638-A1 Natural product inhibitors of 3dg Inactive 30-May-2008 000000000
US-20170049719-A1 Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes Active 08-Apr-2008 0000000000
US-9486418-B2 Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes Inactive 08-Apr-2008 0000000000 0
US-20090253804-A1 Method for treating or preventing dry eye disorders using alkylamino-polyhydroxyalkanes Active 08-Apr-2008 A61K31/133 0
To view MEG 21 with Supplamine’s complete patent history, request access »

MEG 21 with Supplamine Executive Team (4)

Name Title Board Seat Contact Info
Annette Tobia Ph.D Co-Founder, Chief Executive Officer, President & Board Member
David Smith Executive Chairman & Board Member
You’re viewing 2 of 4 executive team members. Get the full list »

MEG 21 with Supplamine Board Members (1)

Name Representing Role Since
David Smith MEG 21 with Supplamine Executive Chairman & Board Member 000 0000
To view MEG 21 with Supplamine’s complete board members history, request access »

MEG 21 with Supplamine Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MEG 21 with Supplamine Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government Minority 000 0000 000000 0
Rohto Pharmaceuticals Corporation Minority 000 0000 000000 0
Connecticut Innovations Venture Capital Minority 000 0000 000000 0
Ben Franklin Technology Partner of Southeastern Pennsylvania Venture Capital Minority 000 0000 000000 0
Fox Chase Cancer Center Corporation Majority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »